Medical imaging is where clinical AI first reached scale. Software now triages suspected strokes, flags fractures on plain films, measures findings automatically and drafts structured reports. As scan volumes rise faster than radiologist capacity, hospitals and imaging centers are buying AI as a turnaround-time tool rather than an experiment.
According to IG Transformation Partners (IGTPS), the global AI medical imaging software market was valued at USD 1.9 billion in 2025 and is projected to reach USD 24.0 billion by 2034, growing at a CAGR of 32.7% from 2026 to 2034. This article examines market size, trends, drivers, segmentation, regional performance and competition for vendors, providers and investors.
Get the Complete AI Medical Imaging Software Market Report
Turn imaging AI data into strategy. The full report provides segment forecasts, regional analysis, competitor coverage and recent developments to guide product, investment and expansion decisions.
Access the Full Market Report: https://www.igtps.com/report/ai-medical-imaging-software-market
What Is the AI Medical Imaging Software Market? Market Overview and Definition
The AI medical imaging software market covers software that uses machine learning and deep learning to read, measure and prioritize medical images from X-ray, CT, MRI, ultrasound and nuclear imaging, delivered on-premises, in the cloud or in hybrid form.
IGTPS segments the market by imaging modality (X-ray, CT, MRI, ultrasound, nuclear imaging and others), application (neurology, oncology, cardiology, pulmonology, musculoskeletal and others), deployment mode (on-premises, cloud-based and hybrid) and end user (hospitals, diagnostic imaging centers, research institutes and others).
The market is shifting from single-disease algorithms toward foundation-model platforms that detect many findings from one scan, and from research pilots toward reimbursed clinical services. Buyers now ask for enterprise contracts, standard integrations and continuous performance monitoring.
AI Medical Imaging Software Market Size, Share and Forecast to 2034
IGTPS values the market at USD 1.9 billion in 2025 and estimates USD 2.5 billion for 2026. By 2034 it is projected to reach USD 24.0 billion, adding roughly USD 22 billion and implying growth of about 12.6 times. The full AI medical imaging software market report covers segments, regions and companies across 170-180 pages with 55-65 market tables.
Market snapshot:
- Study period: 2021-2034
- Market size in 2025: USD 1.9 billion
- Market size in 2026: USD 2.5 billion
- Forecast market size in 2034: USD 24.0 billion
- Projected CAGR (2026-2034): 32.7%
- Largest region: North America
- Fastest-growing region: Asia-Pacific
- Fastest-growing imaging modality: Ultrasound
North America held 45% of the market in 2025 and Europe 25%, according to IGTPS. Asia-Pacific held 22% in 2025 and is projected to reach about 33% by 2034.
A July 2026 study in Cureus, based on the FDA’s public list of AI-enabled devices, counted 1,430 authorizations through December 2025. Radiology accounted for 1,094 of them, or about 76 percent, and 2025 alone added 331 authorizations.
Key AI Medical Imaging Software Market Trends and Developments
- Foundation models and multi-finding triage. Developers are moving from one-algorithm-per-disease products to foundation models trained on large sets of scans, lowering the cost of adding each new indication. Aidoc received FDA clearance for a rib fracture triage tool built on its CARE1 foundation model, described by the company as the first such clearance.
- Enterprise platforms as the delivery layer. Hospitals prefer one integration, one governance dashboard and one contract. Platform owners now host third-party algorithms next to their own, so control of distribution is a competitive asset.
- Report drafting. Several vendors are developing systems that draft findings text from chest X-rays and CT scans for radiologist review. The FDA has stated that it will explore ways to tag devices that use foundation models.
- Expansion into MRI. Gleamer acquired Pixyl and Caerus Medical in March 2025, adding MRI to its X-ray, mammography and CT portfolio.
- Cloud-first platforms. GE HealthCare completed its acquisition of Intelerad in March 2026 for a base purchase price of USD 2.3 billion in cash, extending its AI and imaging portfolio into ambulatory care and teleradiology.
- Broader indications. Qure.ai received FDA 510(k) clearance in February 2026 for qXR-Detect, adding six indications and taking its total FDA-cleared indications to 26.
AI Medical Imaging Software Market Growth Drivers
Imaging volumes and radiologist workload. Imaging demand continues to outpace workforce growth in many health systems, lengthening reading queues. AI triage moves suspected critical scans to the top of the worklist. IGTPS names this the key driver.
Safety net for high-volume reading. Fracture detection software now carries FDA clearance for adults and for children older than two years, giving emergency departments a validated second look.
AI built into scanners. GE HealthCare reports that its deep-learning MRI reconstruction cuts scan time by up to 50 percent, and Philips has added AI reconstruction to its latest spectral CT. Because the software ships with the scanner, adoption follows the equipment replacement cycle.
Regulatory flexibility. The FDA’s final guidance on predetermined change control plans, issued in December 2024, lets manufacturers update cleared algorithms within pre-agreed limits without a new submission each time. The provisional May 2026 agreement on the EU Digital Omnibus moves high-risk obligations for AI in regulated products to 2 August 2028.
Market Restraints and Challenges
A crowded, fragmented field makes scale difficult. IGTPS cites a study of the FDA’s AI-enabled device list that found about 740 manufacturers with authorizations, roughly 68% of them holding a single device, and only 13 companies accounting for about 17% of all authorizations. Single-product vendors may struggle to build broad platforms.
Distribution control is shifting toward platforms. As hospitals prefer one integration and one contract, independent vendors depend on marketplaces and platform owners for access to customers, which can limit pricing power.
Regulatory scrutiny is rising for newer technology. The FDA has said it will explore ways to tag devices that use foundation models, and EU obligations for AI in regulated products will apply from August 2028. Developers need to prepare technical documentation and human-oversight controls. Integration with PACS and EHR systems and the need for proven turnaround-time gains remain key success factors.
Market Opportunities and Future Outlook
IGTPS identifies opportunistic screening and public health programs as new revenue pools. Routine CT scans ordered for other reasons often contain unreported signs of heart, bone and liver disease, and AI can flag coronary calcium, low bone density and fatty liver without extra imaging.
Public health programs in high-burden countries need low-cost chest X-ray reading, and the WHO has recommended computer-aided detection for tuberculosis screening on chest X-rays since 2021. In the United Kingdom, the EDITH trial, backed by about USD 13.8 million (GBP 11 million) through the NIHR, will invite nearly 700,000 women at 30 sites to test whether one radiologist with AI support can replace two readers per mammogram.
Drug developers are a second buyer group, using imaging biomarker automation and trial analytics. By 2034, expect foundation models, multi-modality portfolios and reimbursed services to define the market.
AI Medical Imaging Software Market Segmentation Analysis
IGTPS segments the market by imaging modality, application, deployment mode and end user. A preview of the report structure is available in the free AI medical imaging software market sample pages.
Segment leaders at a glance:
- Imaging modality: Computed tomography leads in 2025, Ultrasound is the fastest-growing
- Application: Neurology leads in 2025, Oncology is the fastest-growing
- Deployment mode: On-premises leads in 2025, Cloud-based is the fastest-growing
- End user: Hospitals lead in 2025, Diagnostic imaging centers are the fastest-growing
Analysis by Imaging Modality
Computed tomography led because of high CT volumes and the use of AI for time-sensitive applications such as stroke assessment, pulmonary embolism detection, lung nodule identification and cardiac imaging. Ultrasound is projected to grow fastest on portable and point-of-care imaging, where AI can provide real-time guidance and automated measurements and reduce operator variability.
Analysis by Application
Neurology led because rapid assessment matters in stroke and acute neurological conditions, and AI can identify abnormalities such as intracranial hemorrhage and large vessel occlusion. Oncology is projected to grow fastest on rising cancer screening volumes and use of AI across detection, characterization and treatment planning.
Analysis by Deployment Mode
On-premises deployment led because organizations want data control, privacy and integration with existing PACS and server investments. Cloud-based deployment is projected to grow fastest because it reduces dedicated hardware needs and is attractive to smaller hospitals, outpatient facilities and imaging networks.
Analysis by End User
Hospitals led because of high examination volumes and concentrated emergency and complex-care services. Diagnostic imaging centers are projected to grow fastest as outpatient groups adopt AI to handle rising screening volumes, and consolidation of imaging chains lets one AI contract cover many sites.
Preview the Study Before You Buy
Check the report structure, segmentation and data coverage. Request the sample pages to see what the study includes. Download Free Sample Pages: https://www.igtps.com/download-free-sample/ai-medical-imaging-software-market?P=03
AI Medical Imaging Software Market Regional Analysis
Regional highlights:
- North America: Largest region with a 45% share in 2025. Key markets are the United States (largest), Canada and Mexico.
- Europe: 25% share in 2025. Key markets are Germany (largest), France, the United Kingdom and Italy.
- Asia-Pacific: Fastest-growing region, rising from a 22% share in 2025 to about 33% by 2034. Key markets are China (largest), India (fastest-growing), Japan and South Korea.
- Latin America: Emerging region led by Brazil (largest) and Chile (fastest-growing).
- Middle East and Africa: Emerging region led by Saudi Arabia (largest) and the UAE (fastest-growing).
North America is led by the United States, supported by advanced healthcare infrastructure, high imaging volumes and established regulatory pathways. Canada is expanding digital health and AI adoption, while Mexico remains at an earlier stage with adoption concentrated in larger hospitals and private providers.
Asia-Pacific benefits from a large healthcare system in China, growing AI-assisted screening demand in India and advanced technology infrastructure in Japan and South Korea. Australia is expanding digital health adoption, and rising healthcare expenditure and chronic disease prevalence are expected to sustain growth.
IGTPS does not publish shares for every region in its public summary.
Competitive Landscape and Key Companies
IGTPS describes the market as fragmented. Scanner makers GE HealthCare, Siemens Healthineers and Philips lead by clearance count, while specialists such as Aidoc, Viz.ai, RapidAI, Lunit and Qure.ai compete on clinical depth and enterprise platforms. Key players include:
- GE HealthCare Technologies Inc. (US)
- Siemens Healthineers AG (Germany)
- Koninklijke Philips N.V. (Netherlands)
- Aidoc Medical Ltd. (Israel)
- Viz.ai, Inc. (US)
- RapidAI (US)
- Lunit Inc. (South Korea)
- Qure.ai (India)
- Heartflow, Inc. (US)
- DeepHealth, Inc. (US)
- Harrison.ai (Australia)
- Cleerly, Inc. (US)
- Brainomix Limited (UK)
- Nano-X Imaging Ltd. (Israel)
Key success factors include breadth of cleared indications, PACS and EHR integration, reimbursement access and proven turnaround-time gains. Reimbursement is progressing: Aetna began covering Cleerly LABS coronary plaque analysis in January 2026, joining UnitedHealthcare, Cigna and Humana, and Cleerly reports that commercial payors covering more than 86 million Americans now support AI-enabled coronary plaque analysis.
Strategic Implications for Industry Participants
- Vendors: Build breadth through foundation models and multi-modality portfolios, and secure PACS, EHR and marketplace distribution.
- Hospitals and imaging centers: Evaluate AI on turnaround time and workload impact, and favor enterprise contracts that cover many sites.
- Public health programs: Consider AI-assisted reading where radiologists are scarce, such as chest X-ray screening for tuberculosis.
- Investors: Watch reimbursement coverage, clearance breadth and consolidation, since they shape which vendors can scale.
Why Choose IG Transformation Partners
IG Transformation Partners offers syndicated research, customized research and consulting services across industries, including life sciences and healthcare IT. Its report pages highlight value chain analysis, growth dynamics, market opportunity assessment, quality assurance and regular report updates. Each report includes a PDF and data sheet with post-sales analyst support, helping vendors, providers and investors compare modalities, applications and regions on a consistent basis.
Conclusion
The AI medical imaging software market is projected to grow from USD 1.9 billion in 2025 to USD 24.0 billion by 2034 at a 32.7% CAGR. CT and neurology lead today, while ultrasound, oncology, cloud delivery and imaging centers drive the next phase. Vendors that combine broad cleared indications, platform distribution and reimbursement access are best placed to benefit.
Frequently Asked Questions
What is the size of the AI medical imaging software market?
IGTPS values the global AI medical imaging software market at USD 1.9 billion in 2025, with an estimated USD 2.5 billion in 2026. The market covers software that reads, measures and prioritizes images from X-ray, CT, MRI, ultrasound and nuclear imaging.
What is the CAGR of the AI medical imaging software market?
The market is projected to grow at a CAGR of 32.7% from 2026 to 2034, according to IGTPS. Growth is supported by rising imaging volumes, radiologist shortages, growing clinical evidence and expanding reimbursement.
What is the AI medical imaging software market forecast for 2034?
IGTPS forecasts the market will reach USD 24.0 billion by 2034. This implies roughly USD 22 billion of added value from the 2025 level of USD 1.9 billion, or growth of about 12.6 times.
What are the key trends in the AI medical imaging software market?
Key trends include foundation models and multi-finding triage, enterprise AI platforms that host third-party algorithms, AI-drafted report text, expansion into MRI and ultrasound, and consolidation such as GE HealthCare’s acquisition of Intelerad.
What is driving the growth of the AI medical imaging software market?
Growth is driven by rising imaging volumes and radiologist workload, validated safety nets such as fracture detection, AI built into scanners, and regulatory flexibility through FDA change control plans and the extended EU deadline.
Which segments lead the AI medical imaging software market?
In 2025, CT led by modality, neurology by application, on-premises by deployment and hospitals by end user. The fastest-growing segments are ultrasound, oncology, cloud-based deployment and diagnostic imaging centers.
Which region dominates the AI medical imaging software market?
North America dominated in 2025 with a 45% share, supported by early FDA clearances and payer coverage. Europe held 25%. Asia-Pacific is projected to grow fastest, rising from 22% to about 33% by 2034.
Who are the key companies in the AI medical imaging software market?
Key players include GE HealthCare, Siemens Healthineers, Philips, Aidoc, Viz.ai, RapidAI, Lunit, Qure.ai, Heartflow, DeepHealth, Harrison.ai, Cleerly, Brainomix and Nano-X Imaging.
What are the main challenges in the AI medical imaging software market?
Challenges include a fragmented field with many single-product vendors, shifting distribution control toward platforms, rising scrutiny of foundation-model devices, and integration requirements with PACS and EHR systems.
What is the future outlook for the AI medical imaging software market?
The outlook is very strong. Foundation models, opportunistic screening, public health programs and cloud delivery should drive growth toward USD 24.0 billion by 2034, with Asia-Pacific gaining share.
Related Market Reports
AI Healthcare Software Market
Covers the wider AI software landscape in healthcare, of which medical imaging is the most mature application.
Explore the Full Report: https://www.igtps.com/report/ai-healthcare-software-market
Comments